Skip to main content
SpringerLink
Log in

nab-Paclitaxel/Gemcitabin als neue Option?

Fortgeschrittenes Pankreaskarzinom

  • In|Fo|Pharm
  • Published:
Info Onkologie Aims and scope

Die Kombinationstherapie scheint der alleinigen Gemcitabin-Gabe hinsichtlich ihrer Wirksamkeit überlegen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Satellitensymposium: „Sharpening the focus on pancreatic adenocarcinoma“ anlässlich des EKK 2013, Amsterdam,Niederlande, 27.09.2013; Veranstalter: prIME Oncology, unterstützt von Celgene

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Annemarie Musch

Authors
  1. Annemarie Musch
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Musch, A. nab-Paclitaxel/Gemcitabin als neue Option?. Info Onkol. 17, 58 (2014). https://doi.org/10.1007/s15004-014-0741-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-014-0741-1

Search

Navigation